In today’s session Kite Pharma Inc (KITE) registered an unusually high (141) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious KITE increase. With 141 contracts traded and 4144 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: KITE161021C00050000 closed last at: $2.95 or 53.9% down. About 56,521 shares traded hands. Kite Pharma Inc (NASDAQ:KITE) has risen 1.58% since March 11, 2016 and is uptrending. It has underperformed by 3.88% the S&P500.
Analysts await Kite Pharma Inc (NASDAQ:KITE) to report earnings on November, 10. They expect $-1.66 EPS, down 163.49% or $1.03 from last year’s $-0.63 per share. After $-1.31 actual EPS reported by Kite Pharma Inc for the previous quarter, Wall Street now forecasts 26.72% negative EPS growth.
Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage
Out of 9 analysts covering Kite Pharma (NASDAQ:KITE), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. $100 is the highest target while $58 is the lowest. The $83.07 average target is 61.14% above today’s ($51.55) stock price. Kite Pharma has been the topic of 22 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Equal-Weight” rating given on Tuesday, August 9 by Barclays Capital. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Outperform” rating given on Tuesday, February 2 by RBC Capital Markets. The rating was maintained by Canaccord Genuity with “Buy” on Friday, August 14. The firm earned “Equal-Weight” rating on Wednesday, July 6 by Barclays Capital. The firm has “Hold” rating by Standpoint Research given on Friday, November 13. On Friday, November 13 the stock rating was maintained by FBR Capital with “Mkt Perform”. The stock of Kite Pharma Inc (NASDAQ:KITE) earned “Buy” rating by Stifel Nicolaus on Friday, November 13. The company was upgraded on Tuesday, January 19 by FBR Capital. The stock of Kite Pharma Inc (NASDAQ:KITE) earned “Buy” rating by Guggenheim on Friday, August 14. The firm earned “Buy” rating on Tuesday, May 10 by Mizuho.
According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”
Insitutional Activity: The institutional sentiment increased to 1.57 in 2016 Q2. Its up 0.38, from 1.19 in 2016Q1. The ratio increased, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.
Price T Rowe Md has 239,742 shares for 0% of their US portfolio. Moreover, State Board Of Administration Of Florida Retirement System has 0% invested in Kite Pharma Inc (NASDAQ:KITE) for 20,883 shares. Mckinley Management Ltd Delaware has 5,712 shares for 0.01% of their US portfolio. Partner Fund Management L P holds 311,765 shares or 0.47% of its portfolio. Fmr Ltd Com owns 2.32M shares or 0.02% of their US portfolio. The Delaware-based Blackrock Advsr Lc has invested 0% in Kite Pharma Inc (NASDAQ:KITE). Spot Trading Ltd, a Illinois-based fund reported 2,133 shares. Tiaa Cref Invest Management Limited owns 167,651 shares or 0.01% of their US portfolio. Da Davidson holds 1,100 shares or 0% of its portfolio. The Connecticut-based Viking Global Investors Ltd Partnership has invested 0.54% in Kite Pharma Inc (NASDAQ:KITE). Columbus Circle Investors owns 16,866 shares or 0.01% of their US portfolio. The New York-based Neuberger Berman Grp Lc has invested 0% in Kite Pharma Inc (NASDAQ:KITE). Jpmorgan Chase & Communication holds 0.04% or 3.17M shares in its portfolio. Pura Vida Invs Ltd Liability Com holds 0.79% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 37,250 shares. Strs Ohio last reported 0% of its portfolio in the stock.
Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 9 insider sales for $2.93 million net activity. Wiezorek Jeffrey had sold 1,500 shares worth $87,362. $509,350 worth of Kite Pharma Inc (NASDAQ:KITE) shares were sold by BUTITTA CYNTHIA M. 14,000 shares were sold by DOUMANI ROY, worth $812,581 on Monday, June 6.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $2.54 billion. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. It currently has negative earnings. The Firm offers engineered autologous cell therapy , which is an approach to the treatment of cancer.
KITE Company Profile
Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Firm offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Firm is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR therapy.
More notable recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Businesswire.com which released: “Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial …” on October 13, 2016, also Fool.com with their article: “How Kite Pharma Could Change Cancer Treatment Forever” published on September 27, 2016, Marketwatch.com published: “Kite Pharma shares rally after study shows cancer drug benefit” on September 26, 2016. More interesting news about Kite Pharma Inc (NASDAQ:KITE) were released by: Finance.Yahoo.com and their article: “Kite Pharma Starts ZUMA-6 Combo Trial on Lymphoma Drug” published on October 10, 2016 as well as Businesswire.com‘s news article titled: “Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry …” with publication date: October 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.